20, AVENUE APPIA – CH-1211 GENEVA 27 – SWITZERLAND – TEL CENTRAL +41 22 791 2111 – FAX CENTRAL +41 22 791 3111 – WWW.WHO.INT
Ref.: C.L.26.2018
The World Health Organization (WHO) presents its compliments to Member States and
Associate Members and has the pleasure of informing that the 41st Expert Committee on Drug
Dependence (ECDD) will meet in Geneva from 12 to 16 November 2018.
The 41st ECDD will convene to review psychoactive substances on their potential to cause
dependence, abuse and harm to health, and their potential therapeutic applications. WHO will
make recommendations to the UN Secretary-General on the need for and level of international
control of these substances.
Member States are invited to collaborate, as in the past, in this process by providing
accurate information as requested in questionnaires concerning substances under review. At its
126th session in January 2010, the Executive Board approved the publication “Guidance on the
WHO review of psychoactive substances for international control” (EB126/2010/REC1, Annex 6) 1
which requires the Secretariat to request relevant information from Ministers of Health in
Member States and to prepare a report for submission to the ECDD.
For this purpose, a questionnaire was designed to gather information on the legitimate use,
harmful use, status of national control and potential impact of international control for each
... substance under evaluation. A list of substances for which Member States will receive
questionnaires is attached.
Kindly note that Member States who submitted questionnaire responses that were reviewed
at the 40th ECDD on cannabis and cannabis-related substances will not be requested to re-submit
questionnaires for those substances for the 41st ECDD. However, if Member States would like to
amend their responses or submit additional information on cannabis and cannabis-related
substances, it is requested that they inform the Secretariat.
It would be appreciated if a person from the Ministry of Health could be designated as the
... focal point responsible for coordinating responses to the questionnaires. A list of focal points
designated by Member States for the 40th ECDD in June 2018 is attached. It is requested that if a
focal point’s contact details (including e-mail address) are to be added or amended, that Member
States inform the Secretariat by 17 September 2018. Any additions or amendments to focal
point designations should be emailed to
[email protected].
1
http://apps.who.int/gb/ebwha/pdf_files/EB126-REC1/B126_REC1-en.pdf.
... ENCLS: (2)
Page 2
C.L.26.2018
If no additions or amendments to focal point details are made by this date, the focal
point from June 2018 will be approached by the Secretariat for questionnaire completion.
Where there is a competent National Authority under the International Drug Control Treaties, it
is kindly requested that the questionnaires be completed in collaboration with such body.
Once the Secretariat has received the contact details, focal points will be given further
instructions and direct access to online questionnaires. The questionnaires will be analysed by
the Secretariat and prepared as a report that will be shared with the Committee for review.
Member States are also encouraged to provide any additional relevant information
(unpublished or published) on substances to be reviewed at the 41st ECDD
to:
[email protected]. This information will be an invaluable contribution to the ECDD
deliberations and all submissions will be treated as confidential.
The World Health Organization takes this opportunity to renew to Member States and
Associate Members the assurance of its highest consideration.
GENEVA, 21 August 2018
Annex 1
41st WHO Expert Committee on Drug Dependence
Member State Questionnaire Substances
SYNTHETIC CANNABINOIDS
ADB-FUBINACA
FUB-AMB(MMB-FUBINACA_AMB-FUBINACA)
ADB-CHMINACA
CUMYL-4CN-BINACA
FENTANYLS
Cyclopropyl fentanyl
Methoxyacetyl fentanyl
Ortho-fluorofentanyl
Parafluoro butyrfentanyl
Paramethoxybutyrfentanyl
(METH)CATHINONE
N-ethylnorpentylone
MEDICINES
Tramadol
Pregabalin
Annex 2
Country Focal Point Position Email
Afghanistan Dr. Shahpoor yousuf
[email protected]
Albania
Chargé du dossier des stupéfiants, des psychotropes et des
Algeria Dr Ghrieb Houria
[email protected]
précurseurs chimiques
Andorra
Angola
Antigua and Barbuda
Argentina María Bisio
[email protected]
Argentina Jessica Anastasio
[email protected]
Argentina
[email protected]
Armenia Hasmik Martirosyan Head of Controlled Substances Management Department
[email protected]
Director
Illicit Drug, International and Research Policy
Alcohol, Tobacco and Other Drugs Branch
Australia Chris Killick-Moran
[email protected]
Population Health and Sport Division
Department of Health
Deputy Head
Austria Mag Raphael Bayer Federal Ministry of Labour, Social Affairs, Health, and Consumer
[email protected]
Protection
Mr Telman Suleyman oglu
Azerbaijan
[email protected]
Mammadhassanov
Bahamas
Bahrain Ms. Samar Yousef Salem
[email protected]
Addl. Secretariat, Health Services Division, Ministry of Health and
Bangladesh Mr. Md. Habibur Rahman Khan
[email protected]
Family Welfare
Barbados Maryam Hinds Director of the Barbados Drug Service
[email protected] with copy to
[email protected]
Belarus
[email protected]
Belgium Mrs Greet Declerck Agence Fédérale des Médicaments et Produits de Santé
[email protected]
Belize
Pharmacien Diplômé d’Etat en service à la Direction de la Pharmacie,
Benin Hope AKOHOUVI AMOU
[email protected]
du Médicament et des Explorations Diagnostiques
Bhutan Dil kumar Subba
[email protected]
Bolivia (Plurinational State of) Maria Julia Carrasco
[email protected]
Ms Sabina Šahman
[email protected]
Bosnia and Herzegovina
Ana Cvijanović
[email protected]
Botswana
Ms. Renata de Morais Souza Manager of Controlled Products
[email protected] and
[email protected]
Brazil
Quirino Cordeiro Junior General Coordinator for Mental Health, Alcohol and other drugs
[email protected]
Brunei Darussalam Ms Hasmilawaty Md Taib
[email protected]
Senior Expert at the ‘Health Promotion and Prophylaxis of Diseases
Bulgaria Mrs Slaveyka Nikolova
[email protected]
and Addictions’
Burkina Faso Dr SAWADOGO W. Casimir
[email protected]
Burundi Dr Aimable BIZOZA
[email protected]
Cambodia Dr Chhit Sophal
[email protected]
Cameroon
Canada Dr. Hanan Abramovici Cannabis Legalization and Regulation Branch, Health Canada
[email protected]
Cape Verde Dra Fernanda Marques
[email protected]
Central African Republic
Chad Dr NGabére Colette Cnsabé
[email protected]
Chile
Ms Wu Hao Officers from International Cooperation Division of Office of National
[email protected]
China
Mr Wang Wei Narcotics Control Commission
[email protected]
Colombia Oscar Ricardo Santana
[email protected];
[email protected]
Comoros
Congo Ghislaine MBELU KANYUNYU Pharmacist
[email protected]
Cook Islands Mr Valentino Wichman
[email protected]
Costa Rica Dr. Francisco Gólcher
[email protected]
Directeur Coordonnateur du Programme National de Lutte contre le
Côte d'Ivoire Dr Ernest Zotoua
[email protected]
Tabagisme, la Toxicomanie et les autres Addictions
Croatia Ms Romana Katalinić
[email protected]
Cuba
Cyprus Dr John Kkolos
[email protected]
Czech Republic Dr Vlastimil Brandejs
[email protected]
Democratic People's Republic of
Dr Kim Jong Guk
Korea Section Chief, Drug Supply and Management department
Democratic Republic of the Congo
Denmark Maria Koch Aabel Danish Health Authority
[email protected]
Djibouti
Dominica
Dominican Republic Dr Elizabeth Ruiz
[email protected] [email protected]
Dominican Republic Francisca Dalia Castillo Sanchez
[email protected]
Ecuador Roberto Enríquez
[email protected]
Narcotics Control Unit at Central
Egypt Administration Of Pharmaceutical
[email protected]
Affairs – Ministry of Health EGYPT
Licenciado JOSÉ MAURICIO BERMÚDEZ
El Salvador
[email protected]
RECINOS
Equatorial Guinea
Eritrea Mr Michael Girmay Haile
[email protected]
Estonia Ms Malle Tiidelepp
[email protected]
Ethiopia Mr Baharu Zewdie Moya Drug Dependency Prevention and Control
[email protected]
Fiji Apolosi Vosanibola Apolosi Vosanibola <
[email protected]>
Finland Dr Katja Pihlainen
[email protected]
France Aldine Fabreguettes
[email protected]
Gabon Docteur Okouyi Ndakissa Senior Specialist, Department of Pharmaceutical Activities
[email protected]
Gambia
Georgia Ketevan Gorozia
[email protected]
Germany Dr. Elke Lehmann
[email protected]
Ghana Mrs Martha Gyansa-Lutterodt Director, Pharmaceutical Services
[email protected]
Greece Ms Ioanna Siamou
[email protected]
Grenada
Departamento de Regulacion y control de productos farmeuticos y
Guatemala Erica Janeth Cohobon Lepe
[email protected]
afines
Guinea
Guinea-Bissau
Guyana
Haiti
Director General del Instituto Hondureño para la Prevención del
Honduras Dr. ALEX VIRGILIO SANTOS MORENO
[email protected] with copy to
[email protected]
Alcoholismo, Drogadicción y Farmacodependencia
Hungary Dr Tímea Kahlesz
[email protected]
Iceland Mr. Einar Magnússon Director of Pharmaceutical Affairs/ Ministry of Welfare
[email protected]
India Prof Rakesh Chadda Chief & HOD, Department of Psychiatry, NDDTC
[email protected]),
Indonesia Dra. Sadiah, Apt, M.Kes Director for Production and Distribution of Pharmaceutical
[email protected]
Indonesia Dr Parulian Sandy Noveria Drug Dependence Hospital Cibubur
[email protected]
Iran (Islamic Republic of)
Iraq Ms. Jamila Zghair Lafta
[email protected]
Ireland Hugh Drumm
[email protected]
Israel Prof. Itamar Grotto
[email protected]
Italy Pietro Canuzzi, MD
[email protected]
Dr Winston De La Haye Ministry of Health
[email protected]
Jamaica Ms Michelle Walker Ministry of Foreign Affairs and Foreign Trade
[email protected]
Ms Lishann Salmon Permanent Mission of Jamaica to the United Nations, Geneva
[email protected]
Sasaki Masahiro sasaki-
[email protected]
Kawase Yasuharu kawase-
Japan
[email protected]
Iwama Shinsuke iwama-
[email protected]
Jordan Dr. Heyam Wahbeh
[email protected]
Kazakhstan Prilutskaya Marina
[email protected]
Dr Simon Njuguna
[email protected]
Kenya
Dr Anthony Toroitich
[email protected]
Kiribati Mr. Biribo Kararaiti
[email protected]
Kuwait Mr Ali Abdulmohsen Jaragh
[email protected]
Kyrgyzstan Kanyshai Damirbek
[email protected]
Lao People's Democratic Republic Dr Khatthanaphone PHANDOUANGSY Head of Health Promotion and Nutrition Unit
[email protected]
Latvia Ms Linda Sīle
[email protected]
Lebanon Dr. Marie-Therese Matar
[email protected]
Lesotho Masello Sello
[email protected]
Liberia
Libya
Lithuania Ms. Ramunė Grigaliūnienė
[email protected]
Luxembourg Dr Alain Origer
[email protected]
Madagascar Mme MAHAVANY Vénot Amélie Nicole
[email protected]
Pharmacien Inspecteur
Malawi
Senior Principle Assistant Director Licensing Branch (Controlled Sub-
Section)
Malaysia Mdm. Rohaida Binti Zakaria Pharmacy Enforcement Division
[email protected]
Ministry of Health Malaysia
Deputy Director General, Pharmaceuticals
Maldives Aishath Mohamed
[email protected]
Medicine and Therapeutic Goods Division,
Mali Dr Mahamadou Ousmane Maiga Chef de Section Reglementation a la Direction de la Pharmacie
[email protected]
Malta Victor P. Pace
[email protected]
Marshall Islands Ms Julia Alfred Secretary of Health
[email protected]
Directeur de la Pharmacie et du Laboratoire
Mauritania Dr Hamoud Fadel Yamohomed
[email protected]
Ministère de la Santé
Mauritius Dr A. Jhugroo Adviser, Substance Abuse
[email protected]
Mexico Mr. Alberto Miguel Guzman
[email protected]
Micronesia (Federated States of) Mr Benido Victor
[email protected]
Monaco Isabelle KESSEDJIAN
[email protected]
Mongolia Luvsandagva Purevdorj
[email protected]
Montenegro Ms Jasna Sekulic Head of the Department for prevention policy of drug abuse
[email protected]
Morocco Dr Hassan Elkarimi
[email protected]
Morocco Prof. Jallal TOUFIQ Directeur, OMDA, CHU Ar-Razi, Salé
[email protected]
Mozambique Dr Eugénia Guelfrida Salesio Teodoro
[email protected]
Myanmar
Namibia Ester Mvula
[email protected]
Nauru Richard Leona
[email protected]
Nepal
Netherlands Ms Liefke Huizinga Sannes, V.E.A. (Victor) <
[email protected]>
New Zealand Emily Kay
[email protected]
New Zealand Emily Kay
[email protected]
Nicaragua Karla Vanessa Delgado Martinez Directora de Farmacia
[email protected]
Niger
Nigeria
Niue Ms Grizelda Mokoia
[email protected]
Norway Anne S. Onsgård Sagabråten
[email protected]
Oman Dr Mahmood Al Abri
[email protected]
Pakistan Muhammad Arif
[email protected]
Ms Marla Ito
[email protected] with copy to
[email protected]
Palau
Clarette Matlab Chief Pharmacist, Chief of Ancillary Services
[email protected] with copy to
[email protected]
Panama
Papua New Guinea Ms Vicky Wari
[email protected];
[email protected]
Paraguay
Peru Judy Madelit Castañeda Alcántara
[email protected]
Philippines Dr. Ivanhoe Escartin
[email protected]
Poland Mr Michał Kidawa National Bureau for Drug Prevention
[email protected]
Portugal Dra. Graça Vilar
[email protected]
Qatar
Republic of Korea Mi Young HYUN
[email protected]
Republic of Moldova Ms. Cristina Josan
[email protected]
Romania Mrs Camelia Bunaciu
[email protected]
Deputy Head of Division, Department of Drug Supply and Medical
Russian Federation Dr Olga Panova
[email protected]
devises regulation of the Ministry of Health
Rwanda
Saint Kitts and Nevis
Saint Lucia Ms Donna Daniel
[email protected]
Saint Vincent and the Grenadines
Samoa Dr Robert Thomsen
[email protected]
San Marino
Sao Tome and Principe
Saudi Arabia Mr. Adnan Alshammary
[email protected]
Senegal Dr Bintou DIA
[email protected]
Serbia Nataša Savić
[email protected]
Seychelles
Sierra Leone
Senior Executive (International Cooperation) / Public Health Group,
Singapore Ong Lay Tin
[email protected]
Ministry of Health, Singapore
Slovakia
Slovenia Joze Hren
[email protected]
Dr Paul Orotaloa ; Mr Stephen
Solomon Islands
[email protected];
[email protected]
Araitewa
Somalia
South Africa
South Sudan
Lidia Fernandez Matellano; Belén
Spain
[email protected];
[email protected]
Escribano Romero
Sri Lanka BMW Balasooriya
[email protected]
Sudan
Suriname
Swaziland
Sweden Bo Pettersson
[email protected]
Switzerland Ms Diane STEBER
[email protected]
Syrian Arab Republic
Tajikistan
Thailand Mrs Khanittha Tontisirin
[email protected]
The former Yugoslav Republic of
Macedonia
Timor-Leste
Togo Dr Mouhoudine YERIMA Responsable de la pharmacovigilance
[email protected]
Tonga Ms Melenaite Mahe
[email protected]
Trinidad and Tobago Dr Rohit Doon Advisor, Health Promotions and Communications
[email protected]
Tunisia
Turkey
Turkmenistan
Tuvalu
Uganda Dr. Sheila Ndyanabangi
[email protected]
Ukraine Rumyanseva Svetlana Stepanovna
[email protected]
United Arab Emirates
United Kingdom of Great Britain
Catherine Crawford
[email protected]
and Northern Ireland
United Republic of Tanzania Dr Sara Maongezi
[email protected]
Senior Program Manager
United States of America Dr Jim Hunter Controlled Substances Staff in the Center for Drug Evaluation &
[email protected]
Research
Uruguay Dr Horacio Porciuncula Area programatica de salud mental
[email protected]
Uzbekistan
Vanuatu Mr Jerry Iaruel
[email protected]
Venezuela (Bolivarian Republic of)
Viet Nam
Yemen
Zambia Dr Nita Besa
[email protected]
Zimbabwe Mrs Dorcas Shirley Sithole Deputy Director Mental Health Services
[email protected]